Pol S - Search Results

1

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).

Carrieri P, Bourlière M, Di Beo V, Lusivika-Nzinga C, Ramier C, Antwerpes S, Protopopescu C, Lacombe JM, Pol S, Fontaine H, Mourad A, Carrat F, Duracinsky M, Marcellin F; ANRS/AFEF HEPATHER Study Group. Carrieri P, et al. Among authors: pol s. Qual Life Res. 2023 Dec;32(12):3427-3438. doi: 10.1007/s11136-023-03496-w. Epub 2023 Aug 16. Qual Life Res. 2023. PMID: 37587323

2

Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.

Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, Berthelot P, Brechot C. Housset C, et al. Among authors: pol s. Hepatology. 1992 Apr;15(4):578-83. doi: 10.1002/hep.1840150404. Hepatology. 1992. PMID: 1551633

3

Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease.

Nalpas B, Driss F, Pol S, Hamelin B, Housset C, Brechot C, Berthelot P. Nalpas B, et al. Among authors: pol s. J Hepatol. 1991 Jan;12(1):70-4. doi: 10.1016/0168-8278(91)90912-u. J Hepatol. 1991. PMID: 1848875

4

[Treatment of chronic viral hepatitis].

Marcellin P, Metreau JM, Pol S, Zoulim F. Marcellin P, et al. Among authors: pol s. Ann Gastroenterol Hepatol (Paris). 1996 Mar-Apr;32(2):85-7. Ann Gastroenterol Hepatol (Paris). 1996. PMID: 8737503 French. No abstract available.

5

Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients.

Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Bréchot C, Nalpas B. Pol S, et al. J Hepatol. 1998 Jul;29(1):12-9. doi: 10.1016/s0168-8278(98)80173-6. J Hepatol. 1998. PMID: 9696487

6

Triggering of acute alcoholic hepatitis by alpha-interferon therapy.

Zylberberg H, Fontaine H, Thépot V, Nalpas B, Bréchot C, Pol S. Zylberberg H, et al. Among authors: pol s. J Hepatol. 1999 Apr;30(4):722-5. doi: 10.1016/s0168-8278(99)80205-0. J Hepatol. 1999. PMID: 10207816

7

[Treatment of chronic hepatitis C: interferon alpha-2b alone or in combination with ribavirin].

Fontaine H, Pol S. Fontaine H, et al. Among authors: pol s. Gastroenterol Clin Biol. 1999 Apr;23(4):541-4. Gastroenterol Clin Biol. 1999. PMID: 10416124 Free article. French. No abstract available.

8

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.

Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon R, Berthelot P, Bréchot C. Pol S, et al. J Hepatol. 1999 Jul;31(1):1-7. doi: 10.1016/s0168-8278(99)80157-3. J Hepatol. 1999. PMID: 10424277 Clinical Trial.

9

Treatment of chronic hepatitis C in special groups.

Pol S, Zylberberg H, Fontaine H, Bréchot C. Pol S, et al. J Hepatol. 1999;31 Suppl 1:205-9. J Hepatol. 1999. PMID: 10622589 Review.

10

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.

Pol S, Nalpas B, Bourlière M, Couzigou P, Tran A, Abergel A, Zarski JP, Berthelot P, Bréchot C. Pol S, et al. Hepatology. 2000 Jun;31(6):1338-44. doi: 10.1053/jhep.2000.8089. Hepatology. 2000. PMID: 10827161 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

917 results

Search Page